News

Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to advance into clinical trials in 2023 CAMBRIDGE, Mass., June 30, 2022...

Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's...

Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March...

Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination...

Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- NeuroSense Therapeutics...

- Patent valid through 2038 - Phase IIb ALS trial expected to commence H1 2022 CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a video presentation with a corporate update from...

- Warrants exercised at $6 per share - Extends cash runway through Q3 2023 CAMBRIDGE, Mass., March 25, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company...